This page contains a Flash digital edition of a book.
Binosto 70mg effervescent tablets Abbreviated Prescribing Information. Please refer to the appropriate Summary of Product Characteristics (SmPC) before prescribing Binosto. Binosto: Binosto 70 mg effervescent tablets contains 70 mg alendronic acid as 91.37 mg of alendronate sodium trihydrate. Indication: Treatment of postmenopausal osteoporosis. Reduces the risk of vertebral and hip fractures. Dosage and Administration: One 70 mg effervescent tablet once weekly. If a dose is missed, take one effervescent tablet in the morning after remembering. Do not take two tablets on the same day. Instead, return to taking one tablet per week, as originally scheduled. Periodically re-evaluate the need for continued treatment on an individual patient basis,


particularly after 5 or more years of use. No dosage adjustment is necessary for the elderly. For oral use. Dissolve in half a glass of plain water. Ensure complete dissolution before drinking and stir if necessary. Consume solution when in a seated or upright position. Drink a further 30 ml or more of plain water following consumption of the solution. Take immediately after waking, at least 30 minutes before the first food, beverage, or medicinal product of the day. Do not chew or dissolve in the mouth. Do not lie down for at least 30 minutes after taking. Contraindications: Hypersensitivity to alendronate or other ingredients; Abnormalities of the oesophagus and other factors which delay oesophageal emptying such as stricture or achalasia; Inability to stand or sit upright for at least


30 minutes; Hypocalcaemia. Warnings and Precautions: Contains sodium. Not recommended for patients with renal impairment where GFR is less than 35 ml/min. Not recommended for use in children below 18 years. Use caution in conditions affecting the upper GI tract. Discontinue use in cases of oesophageal reaction. Use caution in cases with a history of cancer therapy, IV administered bisphosphonates and dental disease due to increased risk of osteonecrosis of the jaw, and encourage good oral hygiene. Interactions: Concomitant food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products may interfere with absorption. Take alendronate at least 30 minutes before taking any other oral medicine. Use caution


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108